RE: Blarney deficit16 Apr 2020 16:51
Maybe ORPH's business model is becoming tangled?
I hope it is - this is a once a 100 yr event and ::::
Trevor Phillips, executive chairman of hVIVO PLC (LON:HVO), caught up with Proactive Investors after reporting good responses in a phase IIb trial of their new universal treatment FLU-v.
The trial hit both its primary and secondary endpoints with a reduction in influenza infection rates and severity and duration of symptoms also observed.
FLU-v product profile is a broad spectrum (A, B and Pandemic strains), stand-alone, single injection influenza vaccine.
Its on youtube.
I hope he's pushing it like buggery.